cd2665 Search Results


escc trcs with cd2665  (MedChemExpress)
92
MedChemExpress escc trcs with cd2665
ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
Escc Trcs With Cd2665, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/escc trcs with cd2665/product/MedChemExpress
Average 92 stars, based on 1 article reviews
escc trcs with cd2665 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
cd2665  (Tocris)
94
Tocris cd2665
ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
Cd2665, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd2665/product/Tocris
Average 94 stars, based on 1 article reviews
cd2665 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cd2665  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology cd2665
ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
Cd2665, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd2665/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
cd2665 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
rarγ-selective antagonist cd2665  (SRI International)
90
SRI International rarγ-selective antagonist cd2665
ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
Rarγ Selective Antagonist Cd2665, supplied by SRI International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rarγ-selective antagonist cd2665/product/SRI International
Average 90 stars, based on 1 article reviews
rarγ-selective antagonist cd2665 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd2665  (ApexBio)
90
ApexBio cd2665
ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
Cd2665, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd2665/product/ApexBio
Average 90 stars, based on 1 article reviews
cd2665 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd2665 (rarγ antagonists, cas 170355-78-9  (Cayman Chemical)
90
Cayman Chemical cd2665 (rarγ antagonists, cas 170355-78-9
ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
Cd2665 (Rarγ Antagonists, Cas 170355 78 9, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd2665 (rarγ antagonists, cas 170355-78-9/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
cd2665 (rarγ antagonists, cas 170355-78-9 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd2665 (rarβ&γ antagonist)  (FUJIFILM)
90
FUJIFILM cd2665 (rarβ&γ antagonist)
ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
Cd2665 (Rarβ&γ Antagonist), supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd2665 (rarβ&γ antagonist)/product/FUJIFILM
Average 90 stars, based on 1 article reviews
cd2665 (rarβ&γ antagonist) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd2665  (Biosynth Carbosynth)
N/A
   Buy from Supplier
cd2665  (Cayman Chemical)
N/A
CD2665 is a selective retinoic acid receptor RAR β and RARγ antagonist Ks 110 306 and 2 250 nM for RARγ RARβ and RARα respectively with no binding at RXRα At 10 M it has
   Buy from Supplier
cd 2665  (Toronto Research Chemicals)
N/A
   Buy from Supplier
cd 2665  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier

Image Search Results


ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of CD2665 on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).

Journal: Clinical and Translational Medicine

Article Title: ZSH‐2208: A novel retinoid with potent anti‐tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis

doi: 10.1002/ctm2.70148

Figure Lengend Snippet: ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of CD2665 on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).

Article Snippet: Additionally, we treated ESCC‐TRCs with CD2665 (MCE, HY‐107437, USA), a selective antagonist of RARγ, and observed a reduction in the expression levels of both TNFAIP3 and TNIP1 at the gene level.

Techniques: Expressing, Sequencing, RNA Sequencing Assay, ChIP-sequencing, Binding Assay, Immunofluorescence, Staining